Exploring Therapeutic Strategies: The Relationship between Metabolic Disorders and FOXO Signalling in Alzheimer's Disease

Parneet      Kaur; Heena      Khan; Amarjot   Kaur   Grewal; Kamal      Dua; Sachin   Kumar   Singh; Gaurav      Gupta; Thakur   Gurjeet   Singh
Abstract

Alzheimer’s disease is an ailment that is linked with the degeneration of the brain cells, and this illness is the main cause of dementia. Metabolic stress affects the activity of the brain in AD via FOXO signaling. The occurrence of AD will significantly surge as the world’s population ages, along with lifestyle changes perceived in current decades, indicating a main contributor to such augmented prevalence. Similarly, metabolic disorders of current adulthood, such as obesity, stroke, and diabetes mellitus, have been observed as the risk-causing factors of AD. Environmental influences induce genetic mutations that result in the development of several diseases. Metabolic disorders develop when individuals are exposed to an environment where food is easily accessible and requires minimal energy expenditure. Obesity and diabetes are among the most significant worldwide health concerns. Obesity arises because of an imbalance between the amount of energy consumed and the amount of energy expended, which is caused by both behavioral and physiological factors. Obesity, insulin resistance syndrome, hypertension, and inflammation are factors that contribute to the worldwide risk of developing diabetes mellitus and neurodegenerative diseases. FOXO transcription factors are preserved molecules that play an important part in assorted biological progressions, precisely in aging as well as metabolism. Apoptosis, cell division and differentiation, oxidative stress, metabolism, and lifespan are among the physiological processes that the FOXO proteins are adept at controlling. In this review, we explored the correlation between signaling pathways and the cellular functions of FOXO proteins. We have also summarized the intricate role of FOXO in AD, with a focus on metabolic stress, and discussed the prospect of FOXO as a molecular link between AD and metabolic disorders.
Keywords: Alzheimer’s disease, FOXO, dementia, diabetes, obesity, oxidative stress.
Graphical Abstract

[1]
Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of Alzheimer disease. JAMA  2009; 302(6): 627-37.
 [http://dx.doi.org/10.1001/jama.2009.1144] [PMID:  19671904]

[2]
Khan H, Tiwari P, Kaur A, Singh TG. Sirtuin acetylation and deacetylation: A complex paradigm in neurodegenerative disease. Mol Neurobiol  2021; 58(8): 3903-17.
 [http://dx.doi.org/10.1007/s12035-021-02387-w] [PMID:  33877561]

[3]
Saklani P, Khan H, Singh TG, Gupta S, Grewal AK. Demethyleneberberine, a potential therapeutic agent in neurodegenerative disorders: A proposed mechanistic insight. Mol Biol Rep  2022; 49(10): 10101-13.
 [http://dx.doi.org/10.1007/s11033-022-07594-9] [PMID:  35657450]

[4]
Prabhakar NK, Khan H, Grewal AK, Singh TG. Intervention of neuroinflammation in the traumatic brain injury trajectory: In vivo and clinical approaches. Int Immunopharmacol  2022; 108: 108902.
 [http://dx.doi.org/10.1016/j.intimp.2022.108902] [PMID:  35729835]

[5]
Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease-associated Aβ oligomers. J Clin Invest  2012; 122(4): 1339-53.
 [http://dx.doi.org/10.1172/JCI57256] [PMID:  22476196]

[6]
Ma T, Trinh MA, Wexler AJ, et al. Suppression of eIF2α kinases alleviates AD-related synaptic plasticity and spatial memory deficits. Nat Neurosci  2013; 16(9): 1299.
 [http://dx.doi.org/10.1038/nn.3486] [PMID:  23933749]

[7]
De Felice FG, Lourenco MV, Ferreira ST. How does brain insulin resistance develop in Alzheimer’s disease? Alzheimers Dement  2014; 10(1S) (Suppl.): S26-32.
 [http://dx.doi.org/10.1016/j.jalz.2013.12.004] [PMID:  24529521]

[8]
Watson GS, Cholerton BA, Reger MA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. Am J Geriatr Psychiatry  2005; 13(11): 950-8.
 [http://dx.doi.org/10.1176/appi.ajgp.13.11.950] [PMID:  16286438]

[9]
Martin B, Golden E, Carlson OD, et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington’s disease. Diabetes  2009; 58(2): 318-28.
 [http://dx.doi.org/10.2337/db08-0799]

[10]
Cai H, Cong W, Ji S, Rothman S, Maudsley S, Martin B. Metabolic dysfunction in Alzheimer’s disease and related neurodegenerative disorders. Curr Alzheimer Res  2012; 9(1): 5-17.
 [http://dx.doi.org/10.2174/156720512799015064] [PMID:  22329649]

[11]
Yan X, Hu Y, Wang B, Wang S, Zhang X. Metabolic dysregulation contributes to the progression of Alzheimer’s disease. Front Neurosci  2020; 14: 530219.
 [http://dx.doi.org/10.3389/fnins.2020.530219] [PMID:  33250703]

[12]
Wellen KE, Thompson CB. Cellular metabolic stress: Considering how cells respond to nutrient excess. Mol Cell  2010; 40(2): 323-32.
 [http://dx.doi.org/10.1016/j.molcel.2010.10.004] [PMID:  20965425]

[13]
Garg N, Singh TG, Khan H, Arora S, Kaur A, Mannan A. Mechanistic interventions of selected Ocimum species in management of diabetes, obesity, and liver disorders: Transformative developments from preclinical to clinical approaches. Biointerface Res Appl Chem  2021; 12(1): 1304-23.
 [http://dx.doi.org/10.33263/BRIAC121.13041323]

[14]
Khan H, Garg N, Singh TG, Kaur A, Thapa K. Calpain inhibitors as potential therapeutic modulators in neurodegenerative diseases. Neurochem Res  2022; 47(5): 1125-49.
 [http://dx.doi.org/10.1007/s11064-021-03521-9] [PMID:  34982393]

[15]
Ahmad M, Tharumalay RD, Din M, Balqis NS. The effects of circadian rhythm disruption towards metabolic stress and mental health: A review. Malays J Sci  2020; 18(1)

[16]
Kalra P, Khan H, Kaur A, Singh TG. Mechanistic insight on autophagy modulated molecular pathways in cerebral ischemic injury: From preclinical to clinical perspective. Neurochem Res  2022; 47(4): 825-43.
 [http://dx.doi.org/10.1007/s11064-021-03500-0] [PMID:  34993703]

[17]
Liu W, Ruiz-Velasco A, Wang S, et al. Metabolic stress-induced cardiomyopathy is caused by mitochondrial dysfunction due to attenuated Erk5 signaling. Nat Commun  2017; 8(1): 494.
 [http://dx.doi.org/10.1038/s41467-017-00664-8] [PMID:  28887535]

[18]
Schoultz I, Söderholm JD, McKay DM. Is metabolic stress a common denominator in inflammatory bowel disease? Inflamm Bowel Dis  2011; 17(9): 2008-18.
 [http://dx.doi.org/10.1002/ibd.21556] [PMID:  21830276]

[19]
Garg C. khan H, Kaur A, Singh TG, Sharma VK, Singh SK. Therapeutic implications of sonic hedgehog pathway in metabolic disorders: Novel target for effective treatment. Pharmacol Res  2022; 179: 106194.
 [http://dx.doi.org/10.1016/j.phrs.2022.106194] [PMID:  35364246]

[20]
Khan H, Gupta A, Singh TG, Kaur A. Mechanistic insight on the role of leukotriene receptors in ischemic-reperfusion injury. Pharmacol Rep  2021; 73(5): 1240-54.
 [http://dx.doi.org/10.1007/s43440-021-00258-8] [PMID:  33818747]

[21]
Gong Y, Chang L, Viola KL, et al. Alzheimer’s disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA  2003; 100(18): 10417-22.
 [http://dx.doi.org/10.1073/pnas.1834302100] [PMID:  12925731]

[22]
Xia W, Yang T, Shankar G, et al. A specific enzyme-linked immunosorbent assay for measuring β-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol  2009; 66(2): 190-9.
 [http://dx.doi.org/10.1001/archneurol.2008.565] [PMID:  19204155]

[23]
van der Vos KE, Coffer PJ. The extending network of FOXO transcriptional target genes. Antioxid Redox Signal  2011; 14(4): 579-92.
 [http://dx.doi.org/10.1089/ars.2010.3419] [PMID:  20673124]

[24]
Jünger MA, Rintelen F, Stocker H, et al. The Drosophila forkhead transcription factor FOXO mediates the reduction in cell number associated with reduced insulin signaling. J Biol  2003; 2(3): 20.
 [http://dx.doi.org/10.1186/1475-4924-2-20] [PMID:  12908874]

[25]
Puig O, Marr MT, Ruhf ML, Tjian R. Control of cell number by Drosophila FOXO: Downstream and feedback regulation of the insulin receptor pathway. Genes Dev  2003; 17(16): 2006-20.
 [http://dx.doi.org/10.1101/gad.1098703] [PMID:  12893776]

[26]
Giannakou ME, Goss M, Jünger MA, Hafen E, Leevers SJ, Partridge L. Long-lived Drosophila with overexpressed dFOXO in adult fat body. Science  2004; 305(5682): 361.
 [http://dx.doi.org/10.1126/science.1098219] [PMID:  15192154]

[27]
Hwangbo DS, Gersham B, Tu MP, Palmer M, Tatar M. Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body. Nature  2004; 429(6991): 562-6.
 [http://dx.doi.org/10.1038/nature02549] [PMID:  15175753]

[28]
Zhao Y, Zhao B. Oxidative stress and the pathogenesis of Alzheimer’s disease. Oxid Med Cell Longev  2013; 2013: 1-10.
 [http://dx.doi.org/10.1155/2013/316523] [PMID:  23983897]

[29]
Wang X, Wang Z, Chen Y, et al. FoxO mediates APP-induced AICD-dependent cell death. Cell Death Dis  2014; 5(5): e1233.
 [http://dx.doi.org/10.1038/cddis.2014.196] [PMID:  24832605]

[30]
Manolopoulos KN, Klotz L-O, Korsten P, Bornstein SR, Barthel A. Linking Alzheimer’s disease to insulin resistance: The FoxO response to oxidative stress. Mol Psychiatry  2010; 15(11): 1046-52.
 [http://dx.doi.org/10.1038/mp.2010.17] [PMID:  20966918]

[31]
Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene  2005; 24(50): 7410-25.
 [http://dx.doi.org/10.1038/sj.onc.1209086] [PMID:  16288288]

[32]
Shi C, Viccaro K, Lee H, Shah K. Cdk5–Foxo3 axis: Initially neuroprotective, eventually neurodegenerative in Alzheimer’s disease models. J Cell Sci  2016; 129(9): 1815-30.
 [http://dx.doi.org/10.1242/jcs.185009] [PMID:  28157684]

[33]
Salih DAM, Brunet A. FoxO transcription factors in the maintenance of cellular homeostasis during aging. Curr Opin Cell Biol  2008; 20(2): 126-36.
 [http://dx.doi.org/10.1016/j.ceb.2008.02.005] [PMID:  18394876]

[34]
Wong HKA, Veremeyko T, Patel N, et al. De-repression of FOXO3a death axis by microRNA-132 and -212 causes neuronal apoptosis in Alzheimer’s disease. Hum Mol Genet  2013; 22(15): 3077-92.
 [http://dx.doi.org/10.1093/hmg/ddt164] [PMID:  23585551]

[35]
Bellinger FP, He QP, Bellinger MT, et al. Association of selenoprotein p with Alzheimer’s pathology in human cortex. J Alzheimers Dis  2008; 15(3): 465-72.
 [http://dx.doi.org/10.3233/JAD-2008-15313] [PMID:  18997300]

[36]
Pradhan R, Yadav SK, Prem NN, et al. Serum FOXO3A: A ray of hope for early diagnosis of Alzheimer’s disease. Mech Ageing Dev  2020; 190: 111290.
 [http://dx.doi.org/10.1016/j.mad.2020.111290] [PMID:  32603667]

[37]
Sanphui P, Biswas SC. FoxO3a is activated and executes neuron death via Bim in response to β-amyloid. Cell Death Dis  2013; 4(5): e625.
 [http://dx.doi.org/10.1038/cddis.2013.148] [PMID:  23661003]

[38]
Qin W, Zhao W, Ho L, et al. Regulation of forkhead transcription factor FoxO3a contributes to calorie restriction-induced prevention of Alzheimer’s disease-type amyloid neuropathology and spatial memory deterioration. Ann N Y Acad Sci  2008; 1147(1): 335-47.
 [http://dx.doi.org/10.1196/annals.1427.024] [PMID:  19076455]

[39]
Jope RS, Johnson GVW. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci  2004; 29(2): 95-102.
 [http://dx.doi.org/10.1016/j.tibs.2003.12.004] [PMID:  15102436]

[40]
Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, Imahori K. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3β and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol  1996; 92(3): 232-41.
 [http://dx.doi.org/10.1007/s004010050513] [PMID:  8870824]

[41]
Ishizawa T, Sahara N, Ishiguro K, et al. Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Am J Pathol  2003; 163(3): 1057-67.
 [http://dx.doi.org/10.1016/S0002-9440(10)63465-7] [PMID:  12937146]

[42]
Phiel CJ, Wilson CA, Lee VMY, Klein PS. GSK-3α regulates production of Alzheimer’s disease amyloid-β peptides. Nature  2003; 423(6938): 435-9.
 [http://dx.doi.org/10.1038/nature01640] [PMID:  12761548]

[43]
Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer’s disease. J Neurochem  2008; 104(6): 1433-9.
 [http://dx.doi.org/10.1111/j.1471-4159.2007.05194.x] [PMID:  18088381]

[44]
Brewster JL, Linseman DA, Bouchard RJ, et al. Endoplasmic reticulum stress and trophic factor withdrawal activate distinct signaling cascades that induce glycogen synthase kinase-3β and a caspase-9-dependent apoptosis in cerebellar granule neurons. Mol Cell Neurosci  2006; 32(3): 242-53.
 [http://dx.doi.org/10.1016/j.mcn.2006.04.006] [PMID:  16765055]

[45]
Valenti L, Rametta R, Dongiovanni P, et al. Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes  2008; 57(5): 1355-62.
 [http://dx.doi.org/10.2337/db07-0714] [PMID:  18316359]

[46]
Martin B, Mattson MP, Maudsley S. Caloric restriction and intermittent fasting: Two potential diets for successful brain aging. Ageing Res Rev  2006; 5(3): 332-53.
 [http://dx.doi.org/10.1016/j.arr.2006.04.002] [PMID:  16899414]

[47]
O’Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci  2011; 34(1): 185-204.
 [http://dx.doi.org/10.1146/annurev-neuro-061010-113613] [PMID:  21456963]

[48]
Claeysen S, Cochet M, Donneger R, Dumuis A, Bockaert J, Giannoni P. Alzheimer culprits: Cellular crossroads and interplay. Cell Signal  2012; 24(9): 1831-40.
 [http://dx.doi.org/10.1016/j.cellsig.2012.05.008] [PMID:  22627093]

[49]
Rajendran L, Annaert W. Membrane trafficking pathways in Alzheimer’s disease. Traffic  2012; 13(6): 759-70.
 [http://dx.doi.org/10.1111/j.1600-0854.2012.01332.x] [PMID:  22269004]

[50]
Seaman MN. Endosome protein sorting: Motifs and machinery. Cell Mol Life Sci  2008; 65(18): 2842-58.
 [http://dx.doi.org/10.1007/s00018-008-8354-1] [PMID:  18726175]

[51]
Tan J, Evin G. β-Site APP-cleaving enzyme 1 trafficking and Alzheimer’s disease pathogenesis. J Neurochem  2012; 120(6): 869-80.
 [http://dx.doi.org/10.1111/j.1471-4159.2011.07623.x] [PMID:  22171895]

[52]
De Strooper B. Proteases and proteolysis in Alzheimer disease: A multifactorial view on the disease process. Physiol Rev  2010; 90(2): 465-94.
 [http://dx.doi.org/10.1152/physrev.00023.2009] [PMID:  20393191]

[53]
Small SA, Kent K, Pierce A, et al. Model‐guided microarray implicates the retromer complex in Alzheimer’s disease. Ann Neurol  2005; 58(6): 909-19.
 [http://dx.doi.org/10.1002/ana.20667] [PMID:  16315276]

[54]
Bonifacino JS, Hurley JH. Retromer. Curr Opin Cell Biol  2008; 20(4): 427-36.
 [http://dx.doi.org/10.1016/j.ceb.2008.03.009] [PMID:  18472259]

[55]
Burd CG. Physiology and pathology of endosome-to-Golgi retrograde sorting. Traffic  2011; 12(8): 948-55.
 [http://dx.doi.org/10.1111/j.1600-0854.2011.01188.x] [PMID:  21382144]

[56]
Sullivan CP, Jay AG, Stack EC, et al. Retromer disruption promotes amyloidogenic APP processing. Neurobiol Dis  2011; 43(2): 338-45.
 [http://dx.doi.org/10.1016/j.nbd.2011.04.002] [PMID:  21515373]

[57]
Tavassoly O, Sato T, Tavassoly I. Inhibition of brain epidermal growth factor receptor activation: A novel target in neurodegenerative diseases and brain injuries. Mol Pharmacol  2020; 98(1): 13-22.
 [http://dx.doi.org/10.1124/mol.120.119909] [PMID:  32350120]

[58]
De Matteis MA, Luini A. Exiting the golgi complex. Nat Rev Mol Cell Biol  2008; 9(4): 273-84.
 [http://dx.doi.org/10.1038/nrm2378] [PMID:  18354421]

[59]
Dorvash M, Farahmandnia M, Tavassoly I. A systems biology roadmap to decode mTOR control system in cancer. Interdiscip Sci  2020; 12(1): 1-11.
 [http://dx.doi.org/10.1007/s12539-019-00347-6] [PMID:  31531812]

[60]
Grewal AK, Singh N, Singh TG. Effects of resveratrol postconditioning on cerebral ischemia in mice: Role of the sirtuin-1 pathway. Can J Physiol Pharmacol  2019; 97(11): 1094-101.
 [http://dx.doi.org/10.1139/cjpp-2019-0188] [PMID:  31340128]

[61]
Micaroni M. The role of calcium in intracellular trafficking. Curr Mol Med  2010; 10(8): 763-73.
 [http://dx.doi.org/10.2174/156652410793384204] [PMID:  20937019]

[62]
Khan H, Sharma K, Kumar A, Kaur A, Singh TG. Therapeutic implications of cyclooxygenase (COX) inhibitors in ischemic injury. Inflamm Res  2022; 71(3): 277-92.
 [http://dx.doi.org/10.1007/s00011-022-01546-6] [PMID:  35175358]

[63]
Khan H, Sharma R, Kaur A, Singh TG. The endocannabioids system and their implications in various disorders. Int J Pharm Sci Rev Res 2018.

[64]
Wang Y, Lin Y, Wang L, et al. TREM2 ameliorates neuroinflammatory response and cognitive impairment via PI3K/AKT/FoxO3a signaling pathway in Alzheimer’s disease mice. Aging  2020; 12(20): 20862-79.
 [http://dx.doi.org/10.18632/aging.104104] [PMID:  33065553]

[65]
Ponugoti B, Dong G, Graves DT. Role of forkhead transcription factors in diabetes-induced oxidative stress. Exp Diabetes Res  2012; 2012: 1-7.
 [http://dx.doi.org/10.1155/2012/939751] [PMID:  22454632]

[66]
Kalogerakis G, Baker AM, Christov S, et al. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease. Clin Sci  2005; 108(6): 497-506.
 [http://dx.doi.org/10.1042/CS20040312] [PMID:  15634192]

[67]
Cameron VA, Mocatta TJ, Pilbrow AP, et al. Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. Hypertension  2006; 47(6): 1155-61.
 [http://dx.doi.org/10.1161/01.HYP.0000222893.85662.cd] [PMID:  16651460]

[68]
Behl T, Bungau S, Kumar K, et al. Pleotropic effects of polyphenols in cardiovascular system. Biomed Pharmacother  2020; 130: 110714.
 [http://dx.doi.org/10.1016/j.biopha.2020.110714] [PMID:  34321158]

[69]
Landreth G. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer’s disease. Curr Alzheimer Res  2007; 4(2): 159-64.
 [http://dx.doi.org/10.2174/156720507780362092] [PMID:  17430241]

[70]
Ghoneum MH, El Sayed NS. Protective effect of Biobran/MGN-3 against sporadic Alzheimer’s disease mouse model: Possible role of oxidative stress and apoptotic pathways. Oxid Med Cell Longev  2021; 2021(1): 8845064.
 [http://dx.doi.org/10.1155/2021/8845064] [PMID:  33574982]

[71]
Cojocaru IM, Cojocaru M, Miu G, Sapira V. Study of interleukin-6 production in Alzheimer’s disease. Rom J Intern Med  2011; 49(1): 55-8.
 [PMID:  22026253]

[72]
Alam Q, Alam MZ, Mushtaq G, et al. Inflammatory process in Alzheimer’s and Parkinson’s diseases: Central role of cytokines. Curr Pharm Des  2016; 22(5): 541-8.
 [http://dx.doi.org/10.2174/1381612822666151125000300] [PMID:  26601965]

[73]
Huang Y, Wilkinson GF, Willars GB. Role of the signal peptide in the synthesis and processing of the glucagon-like peptide-1 receptor. Br J Pharmacol  2010; 159(1): 237-51.
 [http://dx.doi.org/10.1111/j.1476-5381.2009.00517.x] [PMID:  20002095]

[74]
Li Y, Tweedie D, Mattson MP, Holloway HW, Greig NH. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J Neurochem  2010; 113(6): 1621-31.
 [http://dx.doi.org/10.1111/j.1471-4159.2010.06731.x] [PMID:  20374430]

[75]
Harder H, Nielsen L, Thi TDT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care  2004; 27(8): 1915-21.
 [http://dx.doi.org/10.2337/diacare.27.8.1915] [PMID:  15277417]

[76]
Liu J, Wei L, Wang Z, et al. Protective effect of Liraglutide on diabetic retinal neurodegeneration via inhibiting oxidative stress and endoplasmic reticulum stress. Neurochem Int  2020; 133: 104624.
 [http://dx.doi.org/10.1016/j.neuint.2019.104624] [PMID:  31794832]

[77]
Smith WW, Norton DD, Gorospe M, et al. Phosphorylation of p66Shc and forkhead proteins mediates Aβ toxicity. J Cell Biol  2005; 169(2): 331-9.
 [http://dx.doi.org/10.1083/jcb.200410041] [PMID:  15837797]

[78]
Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T. Pioglitazone improved cognition in a pilot study on patients with Alzheimer’s disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc  2009; 57(1): 177-9.
 [http://dx.doi.org/10.1111/j.1532-5415.2009.02067.x] [PMID:  19170800]

[79]
Pan X, Zhang Y, Kim HG, Liangpunsakul S, Dong XC. FOXO transcription factors protect against the diet-induced fatty liver disease. Sci Rep  2017; 7(1): 44597.
 [http://dx.doi.org/10.1038/srep44597] [PMID:  28300161]

[80]
Gross DN, Wan M, Birnbaum MJ. The role of FOXO in the regulation of metabolism. Curr Diab Rep  2009; 9(3): 208-14.
 [http://dx.doi.org/10.1007/s11892-009-0034-5] [PMID:  19490822]

[81]
Abd-Elbaset M, Mansour AM, Ahmed OM, Abo-Youssef AM. The potential chemotherapeutic effect of β-ionone and/or sorafenib against hepatocellular carcinoma via its antioxidant effect, PPAR-γ, FOXO-1, Ki-67, Bax, and Bcl-2 signaling pathways. Naunyn Schmiedebergs Arch Pharmacol  2020; 393(9): 1611-24.
 [http://dx.doi.org/10.1007/s00210-020-01863-9] [PMID:  32270258]

[82]
Kang CH, Jayasooriya RGPT, Choi YH, Moon SK, Kim WJ, Kim GY. β-Ionone attenuates LPS-induced pro-inflammatory mediators such as NO, PGE2 and TNF-α in BV2 microglial cells via suppression of the NF-κB and MAPK pathway. Toxicol In Vitro  2013; 27(2): 782-7.
 [http://dx.doi.org/10.1016/j.tiv.2012.12.012] [PMID:  23268108]

[83]
Wang S, Xia P, Huang G, et al. FoxO1-mediated autophagy is required for NK cell development and innate immunity. Nat Commun  2016; 7(1): 11023.
 [http://dx.doi.org/10.1038/ncomms11023] [PMID:  27010363]

[84]
Nagashima T, Shigematsu N, Maruki R, et al. Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: Improvement of fasting glycemia in diabetic db/db mice. Mol Pharmacol  2010; 78(5): 961-70.
 [http://dx.doi.org/10.1124/mol.110.065714] [PMID:  20736318]

[85]
Ding H, Tang Z, Tang N, et al. Protective properties of FOXO1 inhibition in a murine model of non-alcoholic fatty liver disease are associated with attenuation of ER stress and necroptosis. Front Physiol  2020; 11: 177.
 [http://dx.doi.org/10.3389/fphys.2020.00177] [PMID:  32218743]

[86]
Li JQ, Yu JT, Jiang T, Tan L. Endoplasmic reticulum dysfunction in Alzheimer’s disease. Mol Neurobiol  2015; 51(1): 383-95.
 [http://dx.doi.org/10.1007/s12035-014-8695-8] [PMID:  24715417]

[87]
Salminen A, Kauppinen A, Suuronen T, Kaarniranta K, Ojala J. ER stress in Alzheimer’s disease: A novel neuronal trigger for inflammation and Alzheimer’s pathology. J Neuroinflammation  2009; 6(1): 41.
 [http://dx.doi.org/10.1186/1742-2094-6-41] [PMID:  20035627]

[88]
Wang L, Zhu X, Sun X, et al. FoxO3 regulates hepatic triglyceride metabolism via modulation of the expression of sterol regulatory-element binding protein 1c. Lipids Health Dis  2019; 18(1): 1-2.
 [http://dx.doi.org/10.1186/s12944-018-0950-y] [PMID:  30611256]

[89]
Marwarha G, Claycombe-Larson K, Lund J, Ghribi O. Palmitate-Induced SREBP1 expression and activation underlies the increased BACE 1 activity and amyloid beta genesis. Mol Neurobiol  2019; 56(7): 5256-69.
 [http://dx.doi.org/10.1007/s12035-018-1451-8] [PMID:  30569418]

[90]
Du S, Zheng H. Role of FoxO transcription factors in aging and age-related metabolic and neurodegenerative diseases. Cell Biosci  2021; 11(1): 188.
 [http://dx.doi.org/10.1186/s13578-021-00700-7] [PMID:  34727995]

[91]
Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. J Diabetes Investig  2013; 4(6): 640-50.
 [http://dx.doi.org/10.1111/jdi.12087] [PMID:  24843720]

[92]
Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: A meta-analysis of prospective studies. Obes Rev  2011; 12(5): e426-37.
 [http://dx.doi.org/10.1111/j.1467-789X.2010.00825.x] [PMID:  21348917]

[93]
Picone P, Di Carlo M, Nuzzo D. Obesity and Alzheimer’s disease: Molecular bases. Eur J Neurosci  2020; 52(8): 3944-50.
 [http://dx.doi.org/10.1111/ejn.14758] [PMID:  32323378]

[94]
Zemva J, Schilbach K, Stöhr O, et al. Central FoxO3a and FoxO6 expression is down-regulated in obesity induced diabetes but not in aging. Exp Clin Endocrinol Diabetes  2011; 120(6): 340-50.
 [http://dx.doi.org/10.1055/s-0031-1297970] [PMID:  22187289]

[95]
Moll L, Schubert M. The role of insulin and insulin-like growth factor-1/FoxO-mediated transcription for the pathogenesis of obesity-associated dementia. Curr Gerontol Geriatr Res  2012; 2012: 1-13.
 [http://dx.doi.org/10.1155/2012/384094] [PMID:  22654904]

[96]
Matsuzaki K, Nakajima A, Guo Y, Ohizumi Y. A narrative review of the effects of citrus peels and extracts on human brain health and metabolism. Nutrients  2022; 14(9): 1847.
 [http://dx.doi.org/10.3390/nu14091847] [PMID:  35565814]

[97]
Kang K, Bai J, Zhong S, et al. Down-regulation of insulin like growth factor 1 involved in alzheimer’s disease via MAPK, Ras, and FoxO signaling pathways. Oxid Med Cell Longev  2022; 2022: 1-15.
 [http://dx.doi.org/10.1155/2022/8169981] [PMID:  35571248]
Cite As
CNS & Neurological Disorders - Drug Targets

Exploring Therapeutic Strategies: The Relationship between Metabolic Disorders and FOXO Signalling in Alzheimer's Disease

Abstract

Graphical Abstract
